In recent months, the name Oxford Biomedica (OXB) has been closely linked with the Oxford University/AstraZeneca Covid-19 vaccine trials. The gene- and cell-therapy specialist has signed a three-year master supply and development agreement with AstraZeneca for the large-scale manufacture of the potential inoculation, and the pharma giant has paid Oxford Biomedica an upfront £15m capacity reservation fee. If the vaccine programme continues, it could receive additional revenues of more than £35m through to the end of 2021.
IC TIP:
Hold
at
850p